These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28297798)

  • 1. [Treatment of non-alcoholic fatty liver disease: an interpretation of the European clinical guidelines for obesity, type 2 diabetes, and digestive disease].
    He FP
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):119-121. PubMed ID: 28297798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An interpretation of European guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease].
    Xin FZ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):403-5. PubMed ID: 27465941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
    Kuchay MS; Choudhary NS; Mishra SK; Misra A
    Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.
    Bril F; Cusi K
    Diabetes Care; 2017 Mar; 40(3):419-430. PubMed ID: 28223446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment.
    Kim KS; Lee BW; Kim YJ; Lee DH; Cha BS; Park CY
    Diabetes Metab J; 2019 Apr; 43(2):127-143. PubMed ID: 30993937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
    Sberna AL; Bouillet B; Rouland A; Brindisi MC; Nguyen A; Mouillot T; Duvillard L; Denimal D; Loffroy R; Vergès B; Hillon P; Petit JM
    Diabet Med; 2018 Mar; 35(3):368-375. PubMed ID: 29247558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes.
    Finer N
    Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():44-54. PubMed ID: 34622555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
    Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
    Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
    Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
    Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations.
    Arrese M; Barrera F; Triantafilo N; Arab JP
    Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):849-866. PubMed ID: 31353974
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study.
    Ming J; Xu S; Gao B; Liu G; Ji Y; Yang F; Jia Y; Fang Y; Ji Q
    Liver Int; 2015 Nov; 35(11):2401-7. PubMed ID: 25879672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expert recommendations on standardized diagnosis and treatment for fatty liver disease in China (2019 revised edition)].
    ; ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2019 Oct; 27(10):748-753. PubMed ID: 31734987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of nonalcoholic fatty liver disease in the Middle East.
    Sanai FM; Abaalkhail F; Hasan F; Farooqi MH; Nahdi NA; Younossi ZM
    World J Gastroenterol; 2020 Jul; 26(25):3528-3541. PubMed ID: 32742124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
    Makri E; Goulas A; Polyzos SA
    Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.
    Saponaro C; Gaggini M; Gastaldelli A
    Curr Diab Rep; 2015 Jun; 15(6):607. PubMed ID: 25894944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials.
    Sáez-Lara MJ; Robles-Sanchez C; Ruiz-Ojeda FJ; Plaza-Diaz J; Gil A
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.
    Arab JP; Dirchwolf M; Álvares-da-Silva MR; Barrera F; Benítez C; Castellanos-Fernandez M; Castro-Narro G; Chavez-Tapia N; Chiodi D; Cotrim H; Cusi K; de Oliveira CPMS; Díaz J; Fassio E; Gerona S; Girala M; Hernandez N; Marciano S; Masson W; Méndez-Sánchez N; Leite N; Lozano A; Padilla M; Panduro A; Paraná R; Parise E; Perez M; Poniachik J; Restrepo JC; Ruf A; Silva M; Tagle M; Tapias M; Torres K; Vilar-Gomez E; Costa Gil JE; Gadano A; Arrese M
    Ann Hepatol; 2020; 19(6):674-690. PubMed ID: 33031970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.